SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report: February 1, 2001
US ONCOLOGY, INC.
-----------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-26190 84-1213501
- -------------- ---------- ------------
(State or Other (Commission (I.R.S.Employer
Jurisdiction of File Number) Identification No.)
Incorporation
or Organization)
16825 Northchase Drive, Suite 1300
Houston, Texas
77060
--------------------------------
(Address of Principal Executive Offices)
(Zip Code)
Registrant's Telephone Number, Including Area Code:
(832) 601-8766
Item 9. REGULATION FD DISCLOSURE
On February 1, 2001, representatives of US Oncology, Inc. will begin making
presentations at analyst and investor conferences using slides containing the
information attached to this Form 8-K as Exhibit 99.2. In the press release
attached to this Form 8-K as Exhibit 99.1, we have announced our intention to
appear at such a conference on February 1, 2001.
We expect to use these slides, in whole or in part and possibly with
modifications, in connection with presentations to investors, analysts and
others during the first quarter of 2001. We are furnishing the text of these
slides pursuant to the Securities and Exchange Commission's Regulation FD.
This information is furnished pursuant to Item 9 of Form 8-K and shall not be
deemed to be "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that Section,
unless we specifically incorporate it by reference in a document filed under
the Securities Act of 1933 or the Securities Exchange Act of 1934. By filing
this report on Form 8-K and furnishing this information, we make no admission as
to the materiality of any information in this report that is required to be
disclosed solely by reason of Regulation FD.
The information contained in the slides is summary information that is intended
to be considered in the context of our SEC filings and other public
announcements that we may make, by press release or otherwise, from time to
time. We undertake no duty or obligation to publicly update or revise the
information contained in this report, although we may do so from time to time as
our management believes is warranted. Any such updating may be made through the
filing of other reports or documents with the SEC, through press releases or
through other public disclosure.
The text of the slides included with this report omits various graphic images
included in the actual slides. We expect to make copies of the actual slides,
including such graphic images, available for viewing at the "Investor
Relations" section of our website located at www.usoncology.com, although we
reserve the right to discontinue that availability at any time.
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS
The following types of statements included in Exhibit 99.2 are or may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995: (i)statements regarding possible or assumed
future results of operations of US Oncology and any statements contained
therein regarding the prospects for any of the Company's services; (ii) any
statements preceded by, followed by or that include the words "believes,"
"expects," "anticipates", "intends", "estimates", "plans" or similar
expressions; and (iii) other statements contained therein regarding matters that
are not historical facts.
US Oncology's business and results of operations are subject to risks and
uncertainties, many of which are beyond the Company's ability to control or
predict. Because of these risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking statements,
and US Oncology stockholders are cautioned not to place undue reliance on such
statements, which speak only as of the date thereof. Factors that could cause
actual results to differ materially include, but are not limited to, government
regulation and enforcement, reimbursement for healthcare services, particularly
including reimbursement for pharmaceuticals, integration of formerly separate
operations in connection with the AOR/PRN merger, changes in cancer therapy or
the manner in which cancer care is delivered, drug utilization, and the
operations of the Company's affiliated physician groups. Please refer to the
Company's Annual Report on Form 10-K for the year ended December 31, 1999,
particularly the section entitled "Risk Factors," and its quarterly reports on
Form 10-Q for the first three quarters of 2000 for a more detailed discussion of
certain of these risks and uncertainties. The cautionary statements contained
or referred to herein or in the Exhibits hereto should be considered in
connection with any written or oral forward-looking statements that may be
issued by US Oncology or persons acting on its behalf. US Oncology does not
undertake any obligation to release any revisions to or to update publicly any
forward-looking statements to reflect events or circumstances after date thereof
or to reflect the occurrence of unanticipated events.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
c) Exhibits
99.1 Press Release dated January 31, 2001
99.2 Text of analyst presentation and investor relations slideshow in use
beginning February 1, 2001.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: February 1, 2001
US ONCOLOGY, INC.
By/s/ Phillip H. Watts
--------------------------------------
Phillip H. Watts
Vice President and General Counsel